Recent stage migration toward low-risk prostate cancer, overtreament of biologically insignificant tumors with radical prostatectomy at the additional expense of a non-negligible morbidity and undertreatment of patients improperly selected for active surveillance are the main reasons that have fuelled the concept of focal therapy. Optimal selection of patients is the key for the successful implementation of focal therapy. Selection criteria for focal therapy vary widely and depend on clinical, histological and imaging characteristics of the patients that are highlighted in this article. In addition, the rationales, merits and limitations of the available methods for the assessment of potential candidates, the evaluation of treatment efficac...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Focal therapy (FT) for the management of clinically localized prostate cancer (PCa) is growing from ...
Recent stage migration toward low-risk prostate cancer, overtreament of biologically insignificant t...
Focal therapy for prostate cancer is a nascent and emerging field. As such, the patient selection cr...
Focal therapy is a promising option for localized prostate cancer treatment in low and intermediate ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
The literature on focal therapy is currently insufficient to recommend it as first-line treatment. W...
Prostate cancer treatment is a controversial topic amongst physicians and patients alike. Radical th...
Focal therapy (FT) may offer a promising treatment option in the field of low to intermediate risk l...
Focal therapy (FT) may offer a promising treatment option in the field of low to intermediate risk l...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
W ith an increasing number of men diagnosed with low-riskprostate cancer because of prostate-specifi...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Focal therapy (FT) for the management of clinically localized prostate cancer (PCa) is growing from ...
Recent stage migration toward low-risk prostate cancer, overtreament of biologically insignificant t...
Focal therapy for prostate cancer is a nascent and emerging field. As such, the patient selection cr...
Focal therapy is a promising option for localized prostate cancer treatment in low and intermediate ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
Focal therapy has emerged as a potential treatment paradigm for men with localized prostate cancer, ...
The literature on focal therapy is currently insufficient to recommend it as first-line treatment. W...
Prostate cancer treatment is a controversial topic amongst physicians and patients alike. Radical th...
Focal therapy (FT) may offer a promising treatment option in the field of low to intermediate risk l...
Focal therapy (FT) may offer a promising treatment option in the field of low to intermediate risk l...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
W ith an increasing number of men diagnosed with low-riskprostate cancer because of prostate-specifi...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Introduction and Objective: Because of the improvements on detection of early stage prostate cancer ...
Focal therapy (FT) for the management of clinically localized prostate cancer (PCa) is growing from ...